Zoonotic Influenza Vaccine Seqirus suspension for injection in pre-filled syringe Zoonotic influenza vaccine (H5N8) (surface antigen
Sponsors
University Of Antwerp, Helse Bergen HF
Conditions
Avian InfluenzaVirus Diseases
Phase 4
A phase IV study to investigate the immunogenicity of the Seqirus licensed MF59 adjuvanted zoonotic influenza vaccine (H5N8) in adults previously vaccinated in 2009 with the Matrix M adjuvanted virosomal influenza (H5N1) vaccine compared to H5 naïve adults.
RecruitingCTIS2025-522593-36-00
Start: 2025-10-15Target: 180Updated: 2025-11-11
Phase IV multicenter immunogenicity and safety study of the Seqirus licensed zoonotic influenza vaccine (H5N8) in adults immunized with an H5N1/MF59 influenza vaccine, approximately 20 years before the trial, compared to H5 naive adult participants.
Active, not recruitingCTIS2025-522116-16-00
Start: 2025-12-08Target: 60Updated: 2025-10-16